he antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients with Covid-19 or prevent them from dying, according to results from a long-awaited clinical trial conducted in China. Gilead, however, said the data suggest a “potential benefit.”“A draft manuscript was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is now undergoing peer review and we are waiting for a final version before WHO comments on it,” said WHO spokesperson Daniela Bagozzi.advertisementGilead...…he antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients with Covid-19 or prevent them from dying, according to results from a long-awaited clinical trial conducted in China. Gilead, however, said the data suggest a “potential benefit.”“A draft manuscript was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is now undergoing peer review and we are waiting for a final version before WHO comments on it,” said WHO spokesperson Daniela Bagozzi.advertisementGilead...WW…

s the impeachment trial for former President Trump plays out, the pharmaceutical industry can thank itself for playing a role — albeit, a small one — in this unseemly national spectacle.Why do I say that? Let’s connect some dots.During the previous two election cycles, the industry donated more than $2.4 million to the Republican Attorneys General Association, which made campaign contributions to the Texas attorney general who filed a challenging results from the presidential election in several states. The association also funded attorneys general from 11 other states who the...…s the impeachment trial for former President Trump plays out, the pharmaceutical industry can thank itself for playing a role — albeit, a small one — in this unseemly national spectacle.Why do I say that? Let’s connect some dots.During the previous two election cycles, the industry donated more than $2.4 million to the Republican Attorneys General Association, which made campaign contributions to the Texas attorney general who filed a challenging results from the presidential election in several states. The association also funded attorneys general from 11 other states who the...WW…

s wealthy governments race to lock in supplies of Covid-19 vaccines, nearly a quarter of the world’s population — mostly in low and middle-income countries — will not have access to a shot until 2022, according to a new analysis.As of mid-November, high income countries, including the European Union bloc, reserved 51% of nearly 7.5 billion doses of different Covid-19 vaccines, although these countries comprise just 14% of the world’s population. Meanwhile, only six of the 13 manufacturers working on Covid-19 vaccine candidates have reached agreements to sell their shots to low and...…s wealthy governments race to lock in supplies of Covid-19 vaccines, nearly a quarter of the world’s population — mostly in low and middle-income countries — will not have access to a shot until 2022, according to a new analysis.As of mid-November, high income countries, including the European Union bloc, reserved 51% of nearly 7.5 billion doses of different Covid-19 vaccines, although these countries comprise just 14% of the world’s population. Meanwhile, only six of the 13 manufacturers working on Covid-19 vaccine candidates have reached agreements to sell their shots to low and...WW…

In-depth analysis of biotech, pharma, and the life sciencesIn-depth analysis of biotech, pharma, and the life sciencesgroup of hospital associations filed a accusing the Department of Health and Human Services of failing to prevent a half dozen large drug makers from curtailing the discounts they offer through a federal program for safety-net hospitals.At issue is the 340B drug discount program, which was created in 1992 and requires drug makers to offer discounts that are typically estimated to be 25% to 50% — but could be much higher — on all outpatient drugs to hospitals and clinics that...…In-depth analysis of biotech, pharma, and the life sciencesIn-depth analysis of biotech, pharma, and the life sciencesgroup of hospital associations filed a accusing the Department of Health and Human Services of failing to prevent a half dozen large drug makers from curtailing the discounts they offer through a federal program for safety-net hospitals.At issue is the 340B drug discount program, which was created in 1992 and requires drug makers to offer discounts that are typically estimated to be 25% to 50% — but could be much higher — on all outpatient drugs to hospitals and clinics that...WW…